Evidence map›Paper›PMID 31858400›Full record

ArticlePituitary2020

Acromegaly in the setting of Tatton-Brown-Rahman Syndrome.

C Hage, E Sabini, H Alsharhan, J A Fahrner, A Beckers, A Daly, R Salvatori

Open access · greenAbstract readCase Reports
PubMed Publisher
In one paragraph

Article in Pituitary, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

C HageDivision of Endocrinology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
E SabiniDeparment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
H AlsharhanMcKusick-Nathans Institute of Genetic Medicine and Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
J A FahrnerMcKusick-Nathans Institute of Genetic Medicine and Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
A BeckersDepartment of Endocrinology, Centre Hospitalier Universitaire de Liège, Liège, Belgium.
A DalyDepartment of Endocrinology, Centre Hospitalier Universitaire de Liège, Liège, Belgium.
R SalvatoriDivision of Endocrinology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA. salvator@jhmi.edu.ORCID http://orcid.org/0000-0001-6495-2244
Johns Hopkins University · USCentre Hospitalier Universitaire de Liège · BEChildren's Hospital of Philadelphia · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTatton-Brown-Rahman syndrome (TBRS) is a newly defined genetic entity characterized by overgrowth and intellectual disability, resulting from germline mutations in the gene encoding DNA methyltransferase 3 alpha (DNMT3A). Affected individuals with benign and malignant tumors have been reported; to our knowledge pituitary adenomas (and other tumors identified in our patient) have not yet been described in this syndrome. CASE: We report the case of a 34-year-old woman with TBRS who developed a GH-secreting pituitary macroadenoma and other benign tumors and cystic lesions involving diverse organ systems. Whole-exome sequencing revealed a heterozygous, likely pathogenic variant (c.700_709 del10, p. Gly234ArgfsX79) in exon7 of DNMT3A, and a heterozygous variant of uncertain significance (c.25 C>T, p.Arg9Trp) in exon 1 of the gene encoding aryl hydrocarbon receptor-interacting protein (AIP). The patient failed somatostatin analog treatment, and underwent surgery. The tumor retained AIP expression, and analysis of tumor DNA indicated the presence of both AIP alleles, consistent with no loss of heterozygosity. These findings suggest that the AIP variant was not the primary driver of pituitary adenoma development.

conclusionOur case suggests that TBRS might be associated with pituitary adenoma and a broader spectrum of tumors than previously thought, making long-term follow up of these patients crucial to identify tumors early, and to elucidate the clinical spectrum of the disorder for optimization of management.

Indexed as

AcromegalyAdultAllelesDNA (Cytosine-5-)-MethyltransferasesDNA Methyltransferase 3AExome SequencingFemaleGrowth HormoneHeterozygoteHumansIntellectual DisabilityIntracellular Signaling Peptides and ProteinsMutationPituitary Neoplasmsaryl hydrocarbon receptor-interacting proteinDNA (Cytosine-5-)-MethyltransferasesDNA Methyltransferase 3ADNMT3A protein, humanGrowth HormoneIntracellular Signaling Peptides and ProteinsAryl hydrocarbon receptor interacting protein (AIP)DNA methyltransferase 3 alpha (DNMT3A)Growth hormone (GH)OvergrowthPituitary adenomaTatton-Brown-Rahman syndrome (TBRS)

Identifiers

PMID31858400
OpenAlexW2995143618

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.